

# Genoveffa Franchini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/82279/publications.pdf>

Version: 2024-02-01

119  
papers

6,550  
citations

47006

47  
h-index

71685

76  
g-index

120  
all docs

120  
docs citations

120  
times ranked

4383  
citing authors

#	ARTICLE	IF	CITATIONS
1	NK cells and monocytes modulate primary HTLV-1 infection. <i>PLoS Pathogens</i> , 2022, 18, e1010416.	4.7	11
2	Transient Viral Activation in Human T Cell Leukemia Virus Type 1-Infected Macaques Treated With Pomalidomide. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	4
3	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. <i>IScience</i> , 2021, 24, 102047.	4.1	16
4	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. <i>Nature Immunology</i> , 2021, 22, 1294-1305.	14.5	20
5	The V2 loop of HIV gp120 delivers costimulatory signals to CD4 <sup>+</sup> T cells through Integrin $\alpha 4\beta 7$ and promotes cellular activation and infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 32566-32573.	7.1	14
6	A Prime/Boost Vaccine Regimen Alters the Rectal Microbiome and Impacts Immune Responses and Viremia Control Post-Simian Immunodeficiency Virus Infection in Male and Female Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	3.4	7
7	Functional properties and sequence variation of HTLV-1 p13. <i>Retrovirology</i> , 2020, 17, 11.	2.0	5
8	Engagement of monocytes, NK cells, and CD4 <sup>+</sup> Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition. <i>PLoS Pathogens</i> , 2020, 16, e1008377.	4.7	14
9	Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. <i>Journal of Virology</i> , 2020, 94, .	3.4	8
10	Essential Role of Human T Cell Leukemia Virus Type 1 <i>orf-I</i> in Lethal Proliferation of CD4 <sup>+</sup> Cells in Humanized Mice. <i>Journal of Virology</i> , 2019, 93, .	3.4	15
11	Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells. <i>Oncolmmunology</i> , 2019, 8, e1546544.	4.6	23
12	Myeloid Cell Crosstalk Regulates the Efficacy of the DNA/ALVAC/gp120 HIV Vaccine Candidate. <i>Frontiers in Immunology</i> , 2019, 10, 1072.	4.8	15
13	p30 protein: a critical regulator of HTLV-1 viral latency and host immunity. <i>Retrovirology</i> , 2019, 16, 42.	2.0	13
14	Role of HTLV-1 <i>orf-I</i> encoded proteins in viral transmission and persistence. <i>Retrovirology</i> , 2019, 16, 43.	2.0	13
15	ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type. <i>PLoS Pathogens</i> , 2019, 15, e1008121.	4.7	19
16	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. <i>Journal of Clinical Investigation</i> , 2019, 129, 1314-1328.	8.2	28
17	Neutrophil Vaccination Dynamics and Their Capacity To Mediate B Cell Help in Rhesus Macaques. <i>Journal of Immunology</i> , 2018, 201, 2287-2302.	0.8	21
18	HIV vaccine candidate activation of hypoxia and the inflammasome in CD14 <sup>+</sup> monocytes is associated with a decreased risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2018, 24, 847-856.	30.7	65

#	ARTICLE	IF	CITATIONS
19	Inhibition of Tunneling Nanotube (TNT) Formation and Human T-cell Leukemia Virus Type 1 (HTLV-1) Transmission by Cytarabine. <i>Scientific Reports</i> , 2018, 8, 11118.	3.3	44
20	Distinct susceptibility of HIV vaccine vector-induced CD4 T cells to HIV infection. <i>PLoS Pathogens</i> , 2018, 14, e1006888.	4.7	26
21	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. <i>Journal of Immunology</i> , 2016, 197, 2726-2737.	0.8	34
22	Analyses of HTLV-1 sequences suggest interaction between ORF-I mutations and HAM/TSP outcome. <i>Infection, Genetics and Evolution</i> , 2016, 45, 420-425.	2.3	12
23	Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. <i>Nature Medicine</i> , 2016, 22, 762-770.	30.7	197
24	Human T Cell Leukemia Virus Type 1 Infection of the Three Monocyte Subsets Contributes to Viral Burden in Humans. <i>Journal of Virology</i> , 2016, 90, 2195-2207.	3.4	46
25	Expression of Alternatively Spliced Human T-Cell Leukemia Virus Type 1 mRNAs Is Influenced by Mitosis and by a Novel <i>cis</i> -Acting Regulatory Sequence. <i>Journal of Virology</i> , 2016, 90, 1486-1498.	3.4	12
26	Identification of novel monocistronic HTLV-1 mRNAs encoding functional Rex isoforms. <i>Retrovirology</i> , 2015, 12, 58.	2.0	5
27	Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E992-9.	7.1	117
28	Co-dependence of HTLV-1 p12 and p8 Functions in Virus Persistence. <i>PLoS Pathogens</i> , 2014, 10, e1004454.	4.7	36
29	Antibody to the gp120 V1/V2 Loops and CD4+ and CD8+ T Cell Responses in Protection from SIVmac251 Vaginal Acquisition and Persistent Viremia. <i>Journal of Immunology</i> , 2014, 193, 6172-6183.	0.8	34
30	The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC in Rhesus Monkeys. <i>Journal of Virology</i> , 2014, 88, 1809-1814.	3.4	62
31	Palmitoylation and p8-Mediated Human T-Cell Leukemia Virus Type 1 Transmission. <i>Journal of Virology</i> , 2014, 88, 2319-2322.	3.4	9
32	Human T-Cell Leukemia/Lymphoma Virus Type 1 p30, but Not p12/p8, Counteracts Toll-Like Receptor 3 (TLR3) and TLR4 Signaling in Human Monocytes and Dendritic Cells. <i>Journal of Virology</i> , 2014, 88, 393-402.	3.4	27
33	Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac251 infection of macaques. <i>Virology</i> , 2014, 450-451, 359-368.	2.4	18
34	Protection Afforded by an HIV Vaccine Candidate in Macaques Depends on the Dose of SIV <sub>mac251</sub> at Challenge Exposure. <i>Journal of Virology</i> , 2013, 87, 3538-3548.	3.4	52
35	Antibodies with High Avidity to the gp120 Envelope Protein in Protection from Simian Immunodeficiency Virus SIV <sub>mac251</sub> Acquisition in an Immunization Regimen That Mimics the RV-144 Thai Trial. <i>Journal of Virology</i> , 2013, 87, 1708-1719.	3.4	130
36	Antibodies to gp120 and PD-1 Expression on Virus-Specific CD8 <sup>+</sup> T Cells in Protection from Simian AIDS. <i>Journal of Virology</i> , 2013, 87, 3526-3537.	3.4	6

#	ARTICLE	IF	CITATIONS
37	Preclinical Evaluation of HIV Eradication Strategies in the Simian Immunodeficiency Virus-Infected Rhesus Macaque: A Pilot Study Testing Inhibition of Indoleamine 2,3-Dioxygenase. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 207-214.	1.1	16
38	Cutting Edge: Novel Vaccination Modality Provides Significant Protection against Mucosal Infection by Highly Pathogenic Simian Immunodeficiency Virus. <i>Journal of Immunology</i> , 2013, 190, 2495-2499.	0.8	41
39	Nonhuman Primate Models for HIV/AIDS Vaccine Development. <i>Current Protocols in Immunology</i> , 2013, 102, 12.14.1-12.14.30.	3.6	45
40	Targeting the Vaginal Mucosa with Human Papillomavirus Pseudovirion Vaccines Delivering Simian Immunodeficiency Virus DNA. <i>Journal of Immunology</i> , 2012, 188, 714-723.	0.8	30
41	Fatal Pancreatitis in Simian Immunodeficiency Virus SIV <sub>mac251</sub> -Infected Macaques Treated with 2,3-Dideoxyinosine and Stavudine following Cytotoxic-T-Lymphocyte-Associated Antigen 4 and Indoleamine 2,3-Dioxygenase Blockade. <i>Journal of Virology</i> , 2012, 86, 108-113.	3.4	24
42	Gp96SIVlg immunization induces potent polyepitope specific, multifunctional memory responses in rectal and vaginal mucosa. <i>Vaccine</i> , 2011, 29, 2619-2625.	3.8	20
43	Suppression of HTLV-1 replication by Tax-mediated rerouting of the p13 viral protein to nuclear speckles. <i>Blood</i> , 2011, 118, 1549-1559.	1.4	49
44	Orf-I and Orf-II-Encoded Proteins in HTLV-1 Infection and Persistence. <i>Viruses</i> , 2011, 3, 861-885.	3.3	42
45	Requirement of the human T-cell leukemia virus p12 and p30 products for infectivity of human dendritic cells and macaques but not rabbits. <i>Blood</i> , 2010, 116, 3809-3817.	1.4	85
46	Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 20738-20743.	7.1	136
47	HTLV-1 p13, a small protein with a busy agenda. <i>Molecular Aspects of Medicine</i> , 2010, 31, 350-358.	6.4	35
48	Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV. <i>Expert Review of Vaccines</i> , 2010, 9, 997-1005.	4.4	52
49	Memory T Cells in Rhesus Macaques. <i>Advances in Experimental Medicine and Biology</i> , 2010, 684, 126-144.	1.6	14
50	Combined Effect of Antiretroviral Therapy and Blockade of IDO in SIV-Infected Rhesus Macaques. <i>Journal of Immunology</i> , 2009, 182, 4313-4320.	0.8	59
51	HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and simian immunodeficiency virus-infected macaques. <i>Aids</i> , 2009, 23, 35-40.	2.2	33
52	Choosing the right memory T cell for HIV. <i>Nature Medicine</i> , 2009, 15, 244-246.	30.7	4
53	In vivo genetic mutations define predominant functions of the human T-cell leukemia/lymphoma virus p12I protein. <i>Blood</i> , 2009, 113, 3726-3734.	1.4	47
54	Reduced Protection from Simian Immunodeficiency Virus SIV <sub>mac251</sub> Infection Afforded by Memory CD8 <sup>+</sup> T Cells Induced by Vaccination during CD4 <sup>+</sup> T-Cell Deficiency. <i>Journal of Virology</i> , 2008, 82, 9629-9638.	3.4	54

#	ARTICLE	IF	CITATIONS
55	Immune Activation Driven by CTLA-4 Blockade Augments Viral Replication at Mucosal Sites in Simian Immunodeficiency Virus Infection. <i>Journal of Immunology</i> , 2008, 180, 5439-5447.	0.8	115
56	Inhibition of T-Cell Receptor Signal Transduction and Viral Expression by the Linker for Activation of T Cells-Interacting p12 I Protein of Human T-Cell Leukemia/Lymphoma Virus Type 1. <i>Journal of Virology</i> , 2007, 81, 9088-9099.	3.4	54
57	Interleukin-15 but Not Interleukin-7 Abrogates Vaccine-Induced Decrease in Virus Level in Simian Immunodeficiency Virusmac251-Infected Macaques. <i>Journal of Immunology</i> , 2007, 178, 3492-3504.	0.8	47
58	Regulatory T-Cell Markers, Indoleamine 2,3-Dioxygenase, and Virus Levels in Spleen and Gut during Progressive Simian Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2007, 81, 11593-11603.	3.4	92
59	Long-Lasting Decrease in Viremia in Macaques Chronically Infected with Simian Immunodeficiency Virus SIVmac251 after Therapeutic DNA Immunization. <i>Journal of Virology</i> , 2007, 81, 1972-1979.	3.4	42
60	Human T-cell Leukemia Virus Type I p30 Nuclear/Nucleolar Retention Is Mediated through Interactions with RNA and a Constituent of the 60 S Ribosomal Subunit. <i>Journal of Biological Chemistry</i> , 2006, 281, 37150-37158.	3.4	30
61	HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. <i>Blood</i> , 2006, 108, 3808-3817.	1.4	299
62	CTLA-4 blockade decreases TGF-beta,IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. <i>Blood</i> , 2006, 108, 3834-3842.	1.4	154
63	Decreased number of CD4+ and CD8+ T cells that express the interleukin-7 receptor in blood and tissues of SIV-infected macaques. <i>Virology</i> , 2006, 356, 188-197.	2.4	22
64	Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4 + T-Cell Loss and Reduces both Systemic and Mucosal Simian-Human Immunodeficiency Virus SHIV KU2 RNA Levels. <i>Journal of Virology</i> , 2006, 80, 3732-3742.	3.4	67
65	Improved Vaccine Protection from Simian AIDS by the Addition of Nonstructural Simian Immunodeficiency Virus Genes. <i>Journal of Immunology</i> , 2006, 176, 85-96.	0.8	61
66	Human T-cell leukemia/lymphoma virus type 1 nonstructural genes and their functions. <i>Oncogene</i> , 2005, 24, 6026-6034.	5.9	97
67	Correlation between viral RNA levels but not immune responses in plasma and tissues of macaques with long-standing SIVmac251 infection. <i>Virology</i> , 2005, 333, 159-168.	2.4	13
68	Vaccine-Induced CD8+Central Memory T Cells in Protection from Simian AIDS. <i>Journal of Immunology</i> , 2005, 175, 3502-3507.	0.8	79
69	Attenuated Poxvirus-Based Simian Immunodeficiency Virus (SIV) Vaccines Given in Infancy Partially Protect Infant and Juvenile Macaques Against Repeated Oral Challenge With Virulent SIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 124-134.	2.1	104
70	Repression of Human T-Cell Leukemia Virus Type 1 and Type 2 Replication by a Viral mRNA-Encoded Posttranscriptional Regulator. <i>Journal of Virology</i> , 2004, 78, 11077-11083.	3.4	74
71	HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. <i>Nature Medicine</i> , 2004, 10, 197-201.	30.7	163
72	Functional simian immunodeficiency virus Gag-specific CD8+ intraepithelial lymphocytes in the mucosae of SIVmac251- or simianâ€‘human immunodeficiency virus KU2-infected macaques. <i>Virology</i> , 2004, 319, 190-200.	2.4	12

#	ARTICLE	IF	CITATIONS
73	Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. <i>Expert Review of Vaccines</i> , 2004, 3, S75-S88.	4.4	94
74	Emergence of Cytotoxic T Lymphocyte Escape Mutants following Antiretroviral Treatment Suspension in Rhesus Macaques Infected with SIVmac251. <i>Virology</i> , 2003, 305, 210-218.	2.4	18
75	T-Cell Control by Human T-Cell Leukemia/Lymphoma Virus Type 1. <i>International Journal of Hematology</i> , 2003, 78, 280-296.	1.6	65
76	Modeling immune intervention strategies for HIV-1 infection of humans in the macaque model. <i>Clinical and Applied Immunology Reviews</i> , 2003, 3, 289-306.	0.4	4
77	Species-specific transformation of T cells by HVMNE. <i>Virology</i> , 2003, 317, 299-307.	2.4	3
78	Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251. <i>Virology</i> , 2003, 312, 181-195.	2.4	21
79	Modeling a Safer Smallpox Vaccination Regimen, for Human Immunodeficiency Virus Type 1 "Infected Patients, in Immunocompromised Macaques. <i>Journal of Infectious Diseases</i> , 2003, 188, 1181-1191.	4.0	46
80	High Frequency of Virus-Specific CD8 + T Cells in the Central Nervous System of Macaques Chronically Infected with Simian Immunodeficiency Virus SIVmac251. <i>Journal of Virology</i> , 2003, 77, 12346-12351.	3.4	14
81	Seizing of T Cells by Human T-Cell Leukemia/Lymphoma Virus Type 1. <i>Advances in Cancer Research</i> , 2003, 89, 69-132.	5.0	70
82	Vaccination of Macaques with Long-Standing SIVmac251 Infection Lowers the Viral Set Point After Cessation of Antiretroviral Therapy. <i>Journal of Immunology</i> , 2002, 169, 5347-5357.	0.8	90
83	Recombinant Canarypox Vaccine-Elicited CTL Specific for Dominant and Subdominant Simian Immunodeficiency Virus Epitopes in Rhesus Monkeys. <i>Journal of Immunology</i> , 2002, 168, 1847-1853.	0.8	38
84	Containment of Simian Immunodeficiency Virus Infection in Vaccinated Macaques: Correlation with the Magnitude of Virus-Specific Pre- and Postchallenge CD4+and CD8+T Cell Responses. <i>Journal of Immunology</i> , 2002, 169, 4778-4787.	0.8	150
85	Cervicovaginal Lamina Propria Lymphocytes: Phenotypic Characterization and Their Importance in Cytotoxic T-Lymphocyte Responses to Simian Immunodeficiency Virus SIV mac251. <i>Journal of Virology</i> , 2002, 76, 9-18.	3.4	50
86	Dominance of CD8 Responses Specific for Epitopes Bound by a Single Major Histocompatibility Complex Class I Molecule during the Acute Phase of Viral Infection. <i>Journal of Virology</i> , 2002, 76, 875-884.	3.4	125
87	Both Mucosal and Systemic Routes of Immunization with the Live, Attenuated NYVAC/Simian Immunodeficiency Virus SIVgpe Recombinant Vaccine Result in Gag-Specific CD8+ T-Cell Responses in Mucosal Tissues of Macaques. <i>Journal of Virology</i> , 2002, 76, 11659-11676.	3.4	80
88	Retroviral proteins that target the major histocompatibility complex class I. <i>Virus Research</i> , 2002, 88, 119-127.	2.2	8
89	A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine. <i>Vaccine</i> , 2002, 20, 3171-3186.	3.8	39
90	Immune intervention strategies for HIV-1 infection of humans in the SIV macaque model. <i>Vaccine</i> , 2002, 20, A52-A60.	3.8	21

#	ARTICLE	IF	CITATIONS
91	Genetic mutation and early onset of T-cell leukemia in pediatric patients infected at birth with HTLV-I. <i>Leukemia Research</i> , 2002, 26, 155-161.	0.8	28
92	Equivalent Immunogenicity of the Highly Attenuated Poxvirus-Based ALVAC-SIV and NYVAC-SIV Vaccine Candidates in SIVmac251-Infected Macaques. <i>Virology</i> , 2002, 304, 125-134.	2.4	41
93	HTLV-1 p12I protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells. <i>Blood</i> , 2001, 98, 823-829.	1.4	102
94	HVMNE, a novel lymphocryptovirus related to Epstein-Barr virus, induces lymphoma in New Zealand White rabbits. <i>Blood</i> , 2001, 98, 2193-2199.	1.4	13
95	Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. <i>Nature Medicine</i> , 2001, 7, 1320-1326.	30.7	231
96	Free Major Histocompatibility Complex Class I Heavy Chain Is Preferentially Targeted for Degradation by Human T-Cell Leukemia/Lymphotropic Virus Type 1 p12 I Protein. <i>Journal of Virology</i> , 2001, 75, 6086-6094.	3.4	118
97	Impairment of Gag-Specific CD8 + T-Cell Function in Mucosal and Systemic Compartments of Simian Immunodeficiency Virus mac251- and Simian-Human Immunodeficiency Virus KU2-Infected Macaques. <i>Journal of Virology</i> , 2001, 75, 11483-11495.	3.4	67
98	Potential of Simian Immunodeficiency Virus (SIV)-Specific CD4+ and CD8+ T Cell Responses by a DNA-SIV and NYVAC-SIV Prime/Boost Regimen. <i>Journal of Immunology</i> , 2001, 167, 7180-7191.	0.8	89
99	Human T-Cell Lymphotropic Virus Type 1 Tax Represses c-Myb-Dependent Transcription through Activation of the NF- $\kappa$ B Pathway and Modulation of Coactivator Usage. <i>Molecular and Cellular Biology</i> , 2001, 21, 7391-7402.	2.3	34
100	Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. <i>Nature Medicine</i> , 2000, 6, 1140-1146.	30.7	174
101	HTLV-I Tax transrepresses the human c-Myb promoter independently of its interaction with CBP or p300. <i>Oncogene</i> , 2000, 19, 2155-2164.	5.9	38
102	Bcl-XL is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. <i>Blood</i> , 2000, 96, 275-281.	1.4	102
103	p53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14ARF $\rightarrow$ MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. <i>Blood</i> , 2000, 95, 3939-3944.	1.4	63
104	The MHC Class I Heavy Chain Is a Common Target of the Small Proteins Encoded by the 3' End of HTLV Type 1 and HTLV Type 2. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1777-1781.	1.1	31
105	Short Communication: Deletion of the p16INK4AGene in ex Vivo Acute Adult T Cell Lymphoma/Leukemia Cells and Methylation of the p16INK4APromoter in HTLV Type I-Infected T Cell Lines. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 709-713.	1.1	20
106	Bcl-XL is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. <i>Blood</i> , 2000, 96, 275-281.	1.4	30
107	Limiting amounts of p27Kip1 correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I-transformed T-cells. <i>Oncogene</i> , 1999, 18, 2441-2450.	5.9	39
108	Mitochondrial targeting of the p13II protein coded by the x-II ORF of human T-cell leukemia/lymphotropic virus type I (HTLV-I). <i>Oncogene</i> , 1999, 18, 4505-4514.	5.9	92

#	ARTICLE	IF	CITATIONS
109	A Lysine-to-Arginine Change Found in Natural Alleles of the Human T-Cell Lymphotropic/Leukemia Virus Type 1 p12 <sup>I</sup> Protein Greatly Influences Its Stability. <i>Journal of Virology</i> , 1999, 73, 6460-6467.	3.4	44
110	Human and Simian T-Cell Leukemia Viruses Type 2 (HTLV-2 and STLV-2 <sub>pan-p</sub> ) Transform T Cells Independently of Jak/STAT Activation. <i>Journal of Virology</i> , 1998, 72, 4408-4412.	3.4	33
111	HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. <i>Nature Medicine</i> , 1995, 1, 321-329.	30.7	74
112	Expression and Characterization of Proteins Produced by mRNAs Spliced into the X Region of the Human T-Cell Leukemia/Lymphotropic Virus Type II. <i>Virology</i> , 1995, 209, 445-456.	2.4	72
113	Highly Attenuated HIV Type 2 Recombinant Poxviruses, but Not HIV-2 Recombinant <i>Salmonella</i> Vaccines, Induce Long-Lasting Protection in Rhesus Macaques. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 909-920.	1.1	64
114	Humoral and Cellular Immune Responses in Rhesus Macaques Infected with Human Immunodeficiency Virus Type 2. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 383-393.	1.1	18
115	In Vitro Infection of Human Macrophages by Human T-Cell Leukemia/Lymphotropic Virus Type I (HTLV-I). <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 1845-1849.	1.1	79
116	A survey of human leukaemias for sequences of a human retrovirus. <i>Nature</i> , 1983, 302, 626-628.	27.8	214
117	Common site of integration of HTLV in cells of three patients with mature T-cell leukaemia-lymphoma. <i>Nature</i> , 1983, 303, 253-256.	27.8	24
118	Chromosomal sublocalization of human c-myb and c-fes cellular onc genes. <i>Nature</i> , 1983, 304, 169-171.	27.8	171
119	Common site of integration of HTLV in cells of three patients with mature T-cell leukaemia-lymphoma: a retraction. <i>Nature</i> , 1983, 305, 340-340.	27.8	20